Novartis' (NVS) MS Drug Achieves Goals In Late-Stage Studies
Zacks Investment Research | Aug 30, 2019 08:04AM ET
Swiss pharma giant Novartis (NYSE:NVS) announced positive results on pipeline candidate ofatumumab (OMB157) from two late-stage studies for the treatment of relapsing forms of multiple sclerosis (RMS).
The phase III ASCLEPIOS I and II studies investigated the efficacy and safety of monthly subcutaneous ofatumumab 20mg versus once-daily oral dose of Sanofi’s (NASDAQ:SNY) Aubagio 14mg in adults with RMS.
Data from the head-to-head studies showed that ofatumumab was superior to Aubagio in MS patients with a favorable safety profile. Both studies met the primary endpoints. Ofatumumab showed a highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as annualized relapse rate (ARR). Key secondary endpoints of delaying time to confirmed disability progression were also met. Novartis plans to initiate submissions to health authorities by the end of 2019.
Ofatumumab works by binding to the CD20 molecule on the B-cell surface and inducing potent B-cell lysis and depletion. If approved, ofatumumab has the potential to become a treatment option for a broad RMS population, including early MS. It will also be the first B-cell therapy that can be self-administered at home.
Novartis initiated a phase III program on ofatumumab in RMS in August 2016 after obtaining rights from Genmab in all indications, including MS, in December 2015. We note that ofatumumab is marketed by the company for oncology indications as an intravenous infusion under the brand name, Arzerra.
Novartis’ shares have gained 3.8% in the year so far against the .
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.